Limited travel of up to 20% may be required, including possible international travel.
ABEC provides integrated biopharmaceutical manufacturing solutions and services. It supports vaccine and antibody production with bioprocess engineering, equipment maintenance, troubleshooting, and repairs, plus design and build of complete bioprocess lines. It offers customized single-use disposable containers, especially Custom Single Run (CSR) products, leveraging 45+ years of design experience. Its goal is to help clients scale manufacturing faster and at lower costs through in-house engineering, global capacity, and long-term partnerships.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Bethlehem, Pennsylvania
Founded
1974
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Paid Holidays
Paid Vacation
Medical, dental and vision insurance
Company paid life insurance
401(k) Company Match
401(k) Retirement Plan
College tuition benefit program
Employee Referral Program
ABEC opens new biopharmaceutical manufacturing facility in Wilson, North Carolina. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Advertisement - ABEC is set to open a new manufacturing facility in Wilson, North Carolina, further strengthening its network of biopharmaceutical process equipment and consumables production. A ribbon-cutting ceremony to mark the occasion is scheduled for 24 September, with company leadership, employees, partners, and community leaders expected to attend. A new hub for bioprocess equipment and consumables. The Wilson facility will produce bioprocess equipment and consumable products used in the development and manufacturing of biologics, vaccines, and related advanced medicines. The site adds to ABEC's existing operations in Bethlehem, Pennsylvania; Springfield, Missouri; and Fermoy and Kells in Ireland, forming an expanded global manufacturing footprint. The company indicated that Wilson was selected in part because of the area's standing as one of the fastest-growing regions in the United States for life sciences activity. The new plant is expected to generate additional manufacturing and technical jobs in eastern North Carolina, contributing to the region's growing industrial base. Leadership highlights commitment to the biopharmaceutical industry. ABEC CEO Scott Pickering commented on the opening: "Opening our Wilson facility represents another important milestone in ABEC's commitment to supporting the global biopharmaceutical industry. This investment expands our manufacturing capabilities, brings us closer to customers in the southeastern US, and reinforces our ability to deliver the industry's most comprehensive portfolio of bioprocess equipment, consumables, and engineering solutions. We are proud to become part of the Wilson community and look forward to building long-term partnerships throughout the region." Facility opening to recognise broad collaboration. The upcoming opening event will include tours of the facility and will recognise the contributions of employees, contractors, community partners, and local authorities who supported the project's development and completion. With the Wilson facility now coming online, ABEC's expanded bioprocess manufacturing capacity places it in a stronger position to serve customers across the southeastern United States and beyond. Never miss a pharmaceutical headline. The pharmaceutical industry moves fast - stay on top of it with its must - read briefings. * The top pharma and life sciences stories, straight to your inbox * The biggest news, features, interviews, and analysis * Dedicated coverage of the key developments driving the global pharmaceutical sector - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call
ABEC, a global leader in biopharmaceutical manufacturing solutions, has opened a new manufacturing facility in Wilson, North Carolina. The official ribbon-cutting ceremony is scheduled for 24 September 2026. The facility will manufacture bioprocess equipment and consumable products used in developing biologics, vaccines, and advanced medicines. It expands ABEC's global manufacturing network, which includes sites in Bethlehem, Pennsylvania; Springfield, Missouri; and two locations in Ireland. Chief Executive Officer Scott Pickering said the investment expands manufacturing capabilities and brings ABEC closer to customers in the southeastern United States. The facility creates new manufacturing and technical employment opportunities in eastern North Carolina. The grand opening event will include facility tours and remarks from ABEC leadership and local community representatives.
ABEC opens new manufacturing facility in Wilson, North Carolina. Grand Opening Ceremony Scheduled for September 24, 2026 BETHLEHEM, Pa., Sept. 10, 2026 /PRNewswire/ - ABEC, a global leader in customized solutions and services for biopharmaceutical manufacturing, today announced the grand opening of its newest manufacturing facility in Wilson, North Carolina. The official ribbon-cutting ceremony and facility opening celebration will take place on September 24, 2026, at 9:00am, bringing together company leadership, employees, partners, and community leaders to mark this significant milestone in ABEC's continued growth. The new Wilson facility expands ABEC's global manufacturing network and strengthens the company's ability to support the rapidly growing biopharmaceutical industry with industry-leading equipment, consumables, and integrated process solutions. Strategically located in one of the nation's fastest-growing life sciences regions, the facility enhances ABEC's manufacturing capacity while creating new high-quality manufacturing and technical employment opportunities in eastern North Carolina. "Opening our Wilson facility represents another important milestone in ABEC's commitment to supporting the global biopharmaceutical industry," said Scott Pickering, Chief Executive Officer of ABEC. "This investment expands our manufacturing capabilities, brings us closer to customers in the southeastern United States, and reinforces our ability to deliver the industry's most comprehensive portfolio of bioprocess equipment, consumables, and engineering solutions. We are proud to become part of the Wilson community and look forward to building long-term partnerships throughout the region." The Wilson facility will manufacture bioprocess equipment and consumable products used in the development and production of life-saving biologics, vaccines, and other advanced medicines. The site complements ABEC's existing manufacturing operations in Bethlehem, Pennsylvania; Springfield, Missouri; Fermoy, Ireland; and Kells, Ireland, further strengthening the company's position as the biopharmaceutical industry's largest dedicated manufacturing network for process equipment and solutions. The grand opening event will include a ribbon-cutting ceremony, facility tours, and remarks from ABEC leadership and local community representatives. The celebration will recognize the collaborative efforts of employees, contractors, community partners, and local officials whose support helped make the project a reality. About ABEC Since 1974, ABEC has been a global leader in delivering engineered process solutions and services for manufacturing in the biotech industry. The majority of the world's pharmaceutical and biotechnology companies are ABEC customers, with many of today's leading therapies manufactured using ABEC-engineered equipment and processes. ABEC's unique value is built on deep experience, complete in-house capabilities, a flexible approach, and long-term credibility. From process development and facility design to equipment manufacturing, installation, and support services, ABEC helps customers reduce cost and time to market while maximizing productivity. SOURCE ABEC, Inc.
ABEC, a global leader in engineered solutions and services for biotechnology manufacturing, has introduced its Advanced Therapy Bioreactor (ATB(TM), a revolutionary platform focused on transforming cell expansion for Advanced Therapy Medicinal Products (ATMPs).
Eat Just and its cultivated meat subsidiary GOOD Meat have reached an agreement in principle to settle their legal dispute* with bioreactor supplier ABEC, according to court documents, although the matter has not yet reached a final resolution.In a letter to Judge Wendy Beetlestone dated February 6, attorneys for both parties explained that they “have engaged in serious settlement negotiations over the past few months and have reached an agreement in principle regarding the framework for a settlement agreement and the material terms.“However, due to the complex nature of the claims, defenses, and counterclaims,” they added, “the parties require additional time to draft a binding agreement.”In a court order filed on February 7, Judge Beetlestone agreed to their request for the court to appoint a magistrate judge as settlement master to facilitate a final resolution, but rejected their request for a 30-day stay on the litigation and all case deadlines.Neither party has responded to a request for comment from AgFunderNews.What is the case about?The legal dispute began in March 2023 when ABEC filed a lawsuit accusing GOOD Meat of breach of contract by failing to pay its bills on time.According to ABEC, GOOD Meat owed $62,649,231.79 for work ABEC had already completed. Eat Just, in turn, claimed that ABEC had breached the terms of their contract.ABEC, which had been working with GOOD Meat on pilot cultivated chicken facilities in California and Singapore, signed an agreement with the startup in August 2021. Under the seven-year deal, ABEC would design, manufacture, install and commission multiple 250,000-liter vessels— “the largest known bioreactors for avian and mammalian cell culture”—for a large-scale facility in the US.Given “financing hurdles,” by November 2022, Eat Just/GOOD Meat “recommended the evaluation of a phased approach, creating five 125,000-L bioreactors instead of four 250,000-L bioreactors,” and the two started corresponding over amendments to their agreement.By March 2023, ABEC said it had had no choice but to take legal action over unpaid bills. Eat Just/GOOD Meat responded by filing a series of counterclaims, arguing that the parties never formally ratified amendments to their original agreement, and that ABEC had simply proceeded as if they had.Speaking to AgFunderNews last year, Eat Just founder and CEO Josh Tetrick said he was “not attempting to raise money for a large-scale cultivated meat facility right now” and was instead focusing on process development at the firm’s plant in Alameda, California, and working on new cell lines he claimed would enable more efficient large-scale production.*The case is ABEC, Inc. v. Eat Just, Inc